GenMark Diagnostics Stock Price, News & Analysis (NASDAQ:GNMK)

$4.24 -0.06 (-1.40 %)
(As of 12/17/2017 04:00 PM ET)
Previous Close$4.24
Today's Range$4.24 - $4.43
52-Week Range$3.63 - $13.67
Volume938,510 shs
Average Volume414,625 shs
Market Capitalization$232.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.66

About GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics logoGenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Receive GNMK News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNMK
CUSIPN/A
Phone760-448-4300

Debt

Debt-to-Equity Ratio0.12%
Current Ratio2.97%
Quick Ratio2.77%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$49.27 million
Price / Sales4.72
Cash FlowN/A
Price / CashN/A
Book Value$0.82 per share
Price / Book5.17

Profitability

Trailing EPS($1.22)
Net Income$-50,600,000.00
Net Margins-116.76%
Return on Equity-100.33%
Return on Assets-57.22%

Miscellaneous

Employees308
Outstanding Shares54,790,000

GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc (NASDAQ:GNMK) issued its quarterly earnings data on Thursday, November, 2nd. The medical equipment provider reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.02. The medical equipment provider earned $11.60 million during the quarter, compared to analyst estimates of $14.56 million. GenMark Diagnostics had a negative return on equity of 100.33% and a negative net margin of 116.76%. The business's revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.27) earnings per share. View GenMark Diagnostics' Earnings History.

When will GenMark Diagnostics make its next earnings announcement?

GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for GenMark Diagnostics.

Where is GenMark Diagnostics' stock going? Where will GenMark Diagnostics' stock price be in 2017?

6 brokerages have issued 1-year price objectives for GenMark Diagnostics' stock. Their forecasts range from $10.00 to $14.00. On average, they expect GenMark Diagnostics' share price to reach $11.80 in the next year. View Analyst Ratings for GenMark Diagnostics.

What are Wall Street analysts saying about GenMark Diagnostics stock?

Here are some recent quotes from research analysts about GenMark Diagnostics stock:

  • 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (12/11/2017)
  • 2. BTIG Research analysts commented, "The fact that ACOR announced this morning that it will discontinue the tozadenant program (stopping dosing in all currently enrolled studies) came as little surprise following last week’s disclosure of safety issues (our thoughts here). Timing was the only marginal surprise, but based on additional analyses, the company determined that the recently instituted weekly white blood cell count screening may not be adequate to fully ensure the safety of patients. Though this morning’s headline has little incremental impact, it does highlight the added pressure on Inbrija (which is delayed itself following the RTF earlier this year) and formally removes the potential for near- term leverage in the business. Maintain Neutral." (11/20/2017)
  • 3. Needham & Company LLC analysts commented, "Editas Medicine announced today results from a pre-clinical study in transgenic mice demonstrating dose-dependent, in vivo editing using EDIT-101 at the 25th Anniversary Congress of the European Society of Gene and Cell Therapy (ESGCT) in Berlin. Editas reported that the onset of CEP290 gene editing was rapid and detectable as early as three days post-delivery, with a further significant increase in editing observed by one week. Our outlook remains unchanged as to the timing and economics of the LCA10 program." (10/19/2017)

Are investors shorting GenMark Diagnostics?

GenMark Diagnostics saw a decline in short interest in November. As of November 15th, there was short interest totalling 7,784,212 shares, a decline of 15.3% from the October 31st total of 9,186,422 shares. Based on an average daily volume of 1,913,898 shares, the days-to-cover ratio is presently 4.1 days. Approximately 15.1% of the company's stock are short sold.

Who are some of GenMark Diagnostics' key competitors?

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the folowing people:

  • James Charles Fox Ph.D., Independent Chairman of the Board (Age 63)
  • Hany Massarany, President, Chief Executive Officer, Director (Age 55)
  • Scott Mendel, Chief Financial Officer (Age 50)
  • Eric Stier, Senior Vice President, General Counsel, Secretary (Age 41)
  • Jennifer Anne Williams, Senior Vice President - Human Resources (Age 43)
  • Michael W. Gleeson, Senior Vice President, North American Commercial Operations (Age 42)
  • Jon Faiz Kayyem Ph.D., Senior Vice President - Research and Development (Age 53)
  • James B. McNally, Senior Vice President, Marketing and Business Development (Age 37)
  • Michael S. Kagnoff, Director (Age 48)
  • Daryl Jay Faulkner, Independent Director (Age 68)

Who owns GenMark Diagnostics stock?

GenMark Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (8.03%), Jennison Associates LLC (6.52%), Artisan Partners Limited Partnership (4.06%), Northpointe Capital LLC (2.84%), Alyeska Investment Group L.P. (1.85%) and Bank of New York Mellon Corp (0.45%). Company insiders that own GenMark Diagnostics stock include Eric Stier, Hany Massarany, Ingo Chakravarty, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.

Who sold GenMark Diagnostics stock? Who is selling GenMark Diagnostics stock?

GenMark Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Wells Fargo & Company MN, Artisan Partners Limited Partnership and Trexquant Investment LP. Company insiders that have sold GenMark Diagnostics company stock in the last year include Eric Stier, Hany Massarany, Jennifer Anne Williams, Jon Faiz Kayyem, Michael Gleeson and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.

Who bought GenMark Diagnostics stock? Who is buying GenMark Diagnostics stock?

GenMark Diagnostics' stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Northpointe Capital LLC, JPMorgan Chase & Co., Granite Investment Partners LLC, Russell Investments Group Ltd., Private Wealth Partners LLC, Jennison Associates LLC and FDx Advisors Inc.. Company insiders that have bought GenMark Diagnostics stock in the last two years include Lisa M Giles and Michael Kagnoff. View Insider Buying and Selling for GenMark Diagnostics.

How do I buy GenMark Diagnostics stock?

Shares of GenMark Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GenMark Diagnostics stock can currently be purchased for approximately $4.24.

How big of a company is GenMark Diagnostics?

GenMark Diagnostics has a market capitalization of $232.33 million and generates $49.27 million in revenue each year. The medical equipment provider earns $-50,600,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. GenMark Diagnostics employs 308 workers across the globe.

How can I contact GenMark Diagnostics?

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]


MarketBeat Community Rating for GenMark Diagnostics (GNMK)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  392
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GenMark Diagnostics (NASDAQ:GNMK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.863.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.00$12.33$14.17$14.71
Price Target Upside: 158.62% upside189.51% upside58.82% upside14.46% upside

GenMark Diagnostics (NASDAQ:GNMK) Consensus Price Target History

Price Target History for GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics (NASDAQ:GNMK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017BTIG ResearchSet Price TargetBuy$11.00N/AView Rating Details
11/3/2017CowenReiterated RatingBuy$10.00N/AView Rating Details
11/3/2017Raymond James FinancialReiterated RatingOutperform -> Market PerformN/AView Rating Details
11/3/2017Needham & Company LLCLower Price TargetBuy -> Buy$15.00 -> $11.00N/AView Rating Details
10/30/2017Canaccord GenuityReiterated RatingBuy$14.00 -> $14.00N/AView Rating Details
9/18/2017Bank of AmericaInitiated CoverageBuy -> Buy$13.00HighView Rating Details
7/29/2016J P Morgan Chase & CoBoost Price TargetOverweight$10.00 -> $13.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

GenMark Diagnostics (NASDAQ:GNMK) Earnings History and Estimates Chart

Earnings by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics (NASDAQ GNMK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.26)N/AView Earnings Details
11/2/2017Q3 2017($0.26)($0.28)$14.56 million$11.60 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.32)($0.37)$12.44 million$12.36 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.28)($0.30)$12.55 million$12.54 millionViewListenView Earnings Details
2/28/2017Q416($0.27)($0.27)$15.03 million$14.90 millionViewListenView Earnings Details
11/3/2016Q316($0.31)($0.27)$10.36 million$10.80 millionViewN/AView Earnings Details
7/28/2016Q216($0.33)($0.30)$9.62 million$12.50 millionViewListenView Earnings Details
5/3/2016Q116($0.29)($0.30)$10.67 million$11.06 millionViewN/AView Earnings Details
2/23/2016Q415($0.27)($0.21)$12.34 million$13.20 millionViewListenView Earnings Details
10/27/2015Q315($0.31)($0.27)$8.24 million$8.80 millionViewListenView Earnings Details
8/6/2015Q215($0.31)($0.29)$7.59 million$7.65 millionViewN/AView Earnings Details
5/5/2015Q115($0.24)($0.24)$10.10 million$10.10 millionViewN/AView Earnings Details
2/24/2015Q414($0.28)($0.21)$9.83 million$9.83 millionViewN/AView Earnings Details
10/30/2014Q314($0.32)($0.23)$5.80 million$6.30 millionViewN/AView Earnings Details
8/11/2014Q214($0.29)($0.27)$4.79 million$6.55 millionViewN/AView Earnings Details
5/6/2014Q114($0.25)($0.21)$6.40 million$7.91 millionViewN/AView Earnings Details
3/11/2014Q413($0.22)($0.21)$6.06 million$6.45 millionViewN/AView Earnings Details
11/12/2013Q313($0.27)($0.24)$4.60 million$4.64 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.26)($0.25)$5.05 million$5.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$9.53 million$11.10 millionViewN/AView Earnings Details
11/10/2011($0.32)($0.31)ViewN/AView Earnings Details
8/5/2011($0.45)($0.39)ViewN/AView Earnings Details
5/9/2011($0.49)($0.56)ViewN/AView Earnings Details
3/3/2011($0.52)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

GenMark Diagnostics (NASDAQ:GNMK) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.17 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS

Dividends

Dividend History for GenMark Diagnostics (NASDAQ:GNMK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

GenMark Diagnostics (NASDAQ GNMK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.50%
Insider Trades by Quarter for GenMark Diagnostics (NASDAQ:GNMK)
Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics (NASDAQ GNMK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/4/2017Michael GleesonSVPSell499$4.70$2,345.30View SEC Filing  
11/20/2017Hany MassaranyInsiderSell8,252$4.74$39,114.48View SEC Filing  
11/20/2017Jennifer Anne WilliamsSVPSell2,719$4.74$12,888.06View SEC Filing  
11/20/2017Scott MendelCFOSell2,879$4.74$13,646.46View SEC Filing  
11/14/2017Scott MendelCFOSell1,777$4.71$8,369.67View SEC Filing  
11/6/2017Michael KagnoffDirectorBuy20,000$4.13$82,600.00View SEC Filing  
11/2/2017Eric StierSVPSell367$7.24$2,657.08View SEC Filing  
11/2/2017Hany MassaranyInsiderSell1,588$7.24$11,497.12View SEC Filing  
11/2/2017Scott MendelCFOSell326$7.24$2,360.24View SEC Filing  
10/2/2017Eric StierSVPSell2,750$9.60$26,400.00View SEC Filing  
9/15/2017Jennifer Anne WilliamsSVPSell38,681$9.08$351,223.48View SEC Filing  
9/11/2017Michael KagnoffDirectorBuy2,500$9.15$22,875.00View SEC Filing  
9/5/2017Eric StierSVPSell311$9.75$3,032.25View SEC Filing  
8/21/2017Hany MassaranyInsiderSell8,311$9.45$78,538.95View SEC Filing  
8/21/2017Michael GleesonSVPSell1,933$9.45$18,266.85View SEC Filing  
8/21/2017Scott MendelCFOSell2,898$9.45$27,386.10View SEC Filing  
8/15/2017Scott MendelCFOSell1,752$10.16$17,800.32View SEC Filing  
8/2/2017Hany MassaranyInsiderSell1,629$10.33$16,827.57View SEC Filing  
8/2/2017Jon Faiz KayyemSVPSell138$10.33$1,425.54View SEC Filing  
8/2/2017Scott MendelCFOSell333$10.33$3,439.89View SEC Filing  
6/2/2017Michael GleesonSVPSell357$12.89$4,601.73View SEC Filing  
5/19/2017Hany MassaranyInsiderSell8,239$12.89$106,200.71View SEC Filing  
5/19/2017Michael GleesonSVPSell1,916$12.89$24,697.24View SEC Filing  
5/19/2017Scott MendelCFOSell2,135$12.89$27,520.15View SEC Filing  
5/16/2017Scott MendelCFOSell1,268$13.43$17,029.24View SEC Filing  
5/2/2017Eric StierSVPSell362$13.34$4,829.08View SEC Filing  
5/2/2017Hany MassaranyInsiderSell1,571$13.34$20,957.14View SEC Filing  
5/2/2017Scott MendelCFOSell232$13.34$3,094.88View SEC Filing  
3/3/2017Michael GleesonSVPSell353$12.29$4,338.37View SEC Filing  
2/21/2017Hany MassaranyInsiderSell33,537$10.08$338,052.96View SEC Filing  
2/21/2017Jon Faiz KayyemSVPSell5,250$10.08$52,920.00View SEC Filing  
2/21/2017Scott MendelCFOSell8,595$10.08$86,637.60View SEC Filing  
2/2/2017Hany MassaranyInsiderSell1,142$11.58$13,224.36View SEC Filing  
2/2/2017Jennifer Anne WilliamsSVPSell332$11.58$3,844.56View SEC Filing  
2/2/2017Scott MendelCFOSell235$11.58$2,721.30View SEC Filing  
1/19/2017Hany MassaranyInsiderSell27,124$12.47$338,236.28View SEC Filing  
1/19/2017Michael GleesonSVPSell9,569$12.47$119,325.43View SEC Filing  
1/19/2017Scott MendelCFOSell9,098$12.47$113,452.06View SEC Filing  
12/5/2016Jennifer Anne WilliamsSVPSell336$11.31$3,800.16View SEC Filing  
12/2/2016Michael GleesonSVPSell357$11.30$4,034.10View SEC Filing  
11/22/2016Michael KagnoffDirectorBuy2,000$11.80$23,600.00View SEC Filing  
11/14/2016Michael KagnoffDirectorBuy2,000$12.50$25,000.00View SEC Filing  
11/2/2016Hany MassaranyInsiderSell1,148$10.30$11,824.40View SEC Filing  
11/2/2016Michael GleesonSVPSell400$10.30$4,120.00View SEC Filing  
9/7/2016Hany MassaranyInsiderSell1,186$8.69$10,306.34View SEC Filing  
9/7/2016Jennifer Anne WilliamsSVPSell523$8.69$4,544.87View SEC Filing  
9/2/2016Jon Faiz KayyemSVPSell133$8.62$1,146.46View SEC Filing  
8/29/2016Jennifer Anne WilliamsSVPSell24,172$8.63$208,604.36View SEC Filing  
8/22/2016Michael GleesonSVPSell7,500$9.00$67,500.00View SEC Filing  
8/12/2016Lisa M GilesDirectorBuy823$9.40$7,736.20View SEC Filing  
8/2/2016Eric StierSVPSell367$9.88$3,625.96View SEC Filing  
8/2/2016Hany MassaranyInsiderSell1,147$9.88$11,332.36View SEC Filing  
6/7/2016Hany MassaranyCEOSell1,188$8.98$10,668.24View SEC Filing  
6/7/2016Michael GleesonSVPSell868$8.80$7,638.40View SEC Filing  
6/3/2016Ingo ChakravartySVPSell184$8.53$1,569.52View SEC Filing  
5/9/2016Ingo ChakravartySVPSell582$5.42$3,154.44View SEC Filing  
5/2/2016Eric StierSVPSell363$5.79$2,101.77View SEC Filing  
5/2/2016Hany MassaranyCEOSell1,160$5.79$6,716.40View SEC Filing  
3/10/2016Michael KagnoffDirectorBuy2,500$4.90$12,250.00View SEC Filing  
3/7/2016Hany MassaranyCEOSell1,193$5.76$6,871.68View SEC Filing  
3/7/2016Michael GleesonSVPSell559$5.76$3,219.84View SEC Filing  
3/2/2016Eric StierSVPSell365$4.87$1,777.55View SEC Filing  
2/9/2016Ingo ChakravartySVPSell697$5.04$3,512.88View SEC Filing  
2/3/2016Hany MassaranyCEOSell9,173$4.99$45,773.27View SEC Filing  
2/3/2016Michael GleesonSVPSell3,083$4.99$15,384.17View SEC Filing  
1/21/2016Hany MassaranyCEOSell648$6.80$4,406.40View SEC Filing  
1/21/2016Michael GleesonSVPSell227$6.80$1,543.60View SEC Filing  
12/8/2015Eric StierSVPSell240$7.26$1,742.40View SEC Filing  
12/8/2015Hany MassaranyCEOSell1,735$7.26$12,596.10View SEC Filing  
12/3/2015Hany MassaranyCEOSell3,571$7.71$27,532.41View SEC Filing  
12/3/2015Michael GleesonSVPSell1,664$7.62$12,679.68View SEC Filing  
11/3/2015Lisa M GilesDirectorBuy4,000$6.60$26,400.00View SEC Filing  
10/30/2015Michael KagnoffDirectorBuy5,000$6.70$33,500.00View SEC Filing  
10/30/2015Scott MendelCFOBuy10,000$6.47$64,700.00View SEC Filing  
10/29/2015Daryl FaulknerDirectorBuy4,000$7.33$29,320.00View SEC Filing  
9/15/2015Jennifer Anne WilliamsSVPSell14,245$9.98$142,165.10View SEC Filing  
9/14/2015Jennifer Anne WilliamsSVPSell9,245$10.00$92,450.00View SEC Filing  
9/11/2015Hany MassaranyCEOSell1,683$9.64$16,224.12View SEC Filing  
9/11/2015Jennifer Anne WilliamsSVPSell18,280$9.99$182,617.20View SEC Filing  
9/4/2015Jennifer Anne WilliamsSVPSell1,867$9.59$17,904.53View SEC Filing  
9/2/2015Hany MassaranyCEOSell3,865$9.62$37,181.30View SEC Filing  
8/24/2015Scott MendelCFOBuy10,000$9.10$91,000.00View SEC Filing  
6/16/2015Hany MassaranyCEOSell1,698$9.12$15,485.76View SEC Filing  
6/4/2015Michael GleesonSVPSell1,595$9.55$15,232.25View SEC Filing  
6/3/2015Hany MassaranyCEOSell3,486$9.47$33,012.42View SEC Filing  
4/9/2015Hany MassaranyCEOSell5,942$11.52$68,451.84View SEC Filing  
3/13/2015Jennifer Anne WilliamsSVPSell30,000$12.56$376,800.00View SEC Filing  
3/11/2015Hany MassaranyCEOSell28,110$11.88$333,946.80View SEC Filing  
3/11/2015Jeffrey Alan HawkinsSVPSell6,832$12.01$82,052.32View SEC Filing  
3/10/2015Jennifer Anne WilliamsSVPSell722$11.83$8,541.26View SEC Filing  
3/10/2015Michael KagnoffDirectorBuy5,000$11.84$59,200.00View SEC Filing  
3/9/2015Ingo ChakravartySVPSell3,310$12.06$39,918.60View SEC Filing  
1/22/2015Hany MassaranyCEOSell5,982$12.88$77,048.16View SEC Filing  
1/7/2015Hany MassaranyCEOSell4,858$13.00$63,154.00View SEC Filing  
12/16/2014Kevin C OboyleDirectorSell291$12.40$3,608.40View SEC Filing  
12/15/2014Eric StierSVPSell235$12.51$2,939.85View SEC Filing  
12/15/2014Hany MassaranyCEOSell1,700$12.51$21,267.00View SEC Filing  
12/4/2014Hany MassaranyCEOSell3,300$12.06$39,798.00View SEC Filing  
12/4/2014Jeffrey Alan HawkinsSVPSell1,350$12.06$16,281.00View SEC Filing  
10/31/2014Jon Faiz KayyemSVPSell6,000$11.01$66,060.00View SEC Filing  
10/8/2014Hany MassaranyCEOSell5,804$9.00$52,236.00View SEC Filing  
10/7/2014Michael GleesonSVPSell55$9.10$500.50View SEC Filing  
9/12/2014Hany MassaranyCEOSell1,678$9.86$16,545.08View SEC Filing  
9/5/2014Hany MassaranyCEOSell3,795$10.04$38,101.80View SEC Filing  
9/5/2014Michael GleesonSVPSell1,833$10.04$18,403.32View SEC Filing  
8/7/2014Michael GleesonSVPSell52$11.15$579.80View SEC Filing  
7/1/2014Jon Faiz KayyemSVPSell6,000$13.60$81,600.00View SEC Filing  
6/11/2014Hany MassaranyCEOSell1,115$11.64$12,978.60View SEC Filing  
6/5/2014Jon Faiz KayyemSVPSell1,483$10.69$15,853.27View SEC Filing  
6/3/2014Hany MassaranyCEOSell2,700$10.67$28,809.00View SEC Filing  
5/29/2014Kevin C OboyleDirectorSell1,603$10.98$17,600.94View SEC Filing  
5/28/2014Jon Faiz KayyemSVPSell6,000$11.06$66,360.00View SEC Filing  
5/8/2014Richard SlanskyCFOSell2,302$9.26$21,316.52View SEC Filing  
4/9/2014Hany MassaranyCEOSell3,985$9.87$39,331.95View SEC Filing  
3/26/2014Jennifer Anne WilliamsSVPSell30,195$9.97$301,044.15View SEC Filing  
3/5/2014Jon Faiz KayyemSVPSell7,355$12.46$91,643.30View SEC Filing  
1/16/2014Jon Faiz KayyemSVPSell50,000$14.05$702,500.00View SEC Filing  
1/7/2014Hany MassaranyCEOSell4,698$13.31$62,530.38View SEC Filing  
12/6/2013Michael GleesonSVPSell2,211$11.14$24,630.54View SEC Filing  
12/4/2013Hany MassaranyCEOSell3,968$11.14$44,203.52View SEC Filing  
10/9/2013Hany MassaranyCEOSell3,925$12.05$47,296.25View SEC Filing  
10/1/2013Jon Faiz KayyemSVPSell6,000$12.14$72,840.00View SEC Filing  
9/4/2013Jeffrey Alan HawkinsSVPSell1,890$11.60$21,924.00View SEC Filing  
9/3/2013Hany MassaranyCEOSell2,354$11.60$27,306.40View SEC Filing  
9/3/2013Jon Faiz KayyemSVPSell1,545$11.60$17,922.00View SEC Filing  
8/20/2013Jon Faiz KayyemSVPSell1,310$10.15$13,296.50View SEC Filing  
7/1/2013Jon Faiz KayyemSVPSell6,000$10.40$62,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GenMark Diagnostics (NASDAQ GNMK) News Headlines

Source:
DateHeadline
GenMark Diagnostics, Inc (GNMK) Expected to Post Quarterly Sales of $15.60 MillionGenMark Diagnostics, Inc (GNMK) Expected to Post Quarterly Sales of $15.60 Million
www.americanbankingnews.com - December 16 at 9:56 AM
Abaxis (ABAX) vs. GenMark Diagnostics (GNMK) Financial SurveyAbaxis (ABAX) vs. GenMark Diagnostics (GNMK) Financial Survey
www.americanbankingnews.com - December 13 at 1:30 AM
Zacks Investment Research Upgrades GenMark Diagnostics (GNMK) to "Hold"Zacks Investment Research Upgrades GenMark Diagnostics (GNMK) to "Hold"
www.americanbankingnews.com - December 11 at 10:10 PM
GenMark Diagnostics (GNMK) vs. Neovasc (NVCN) Critical ContrastGenMark Diagnostics (GNMK) vs. Neovasc (NVCN) Critical Contrast
www.americanbankingnews.com - December 4 at 9:10 AM
GenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Hold" from BrokeragesGenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 4 at 8:44 AM
GenMark Diagnostics (GNMK) Upgraded to Hold at Zacks Investment ResearchGenMark Diagnostics (GNMK) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - November 29 at 10:26 PM
$15.60 Million in Sales Expected for GenMark Diagnostics, Inc. (GNMK) This Quarter$15.60 Million in Sales Expected for GenMark Diagnostics, Inc. (GNMK) This Quarter
www.americanbankingnews.com - November 28 at 9:50 AM
Short Interest in GenMark Diagnostics, Inc. (GNMK) Drops By 15.3%Short Interest in GenMark Diagnostics, Inc. (GNMK) Drops By 15.3%
www.americanbankingnews.com - November 28 at 3:02 AM
GenMark Diagnostics, Inc. (GNMK) Expected to Announce Earnings of -$0.24 Per ShareGenMark Diagnostics, Inc. (GNMK) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - November 26 at 11:18 AM
GenMark Diagnostics, Inc. (GNMK) SVP Sells $12,888.06 in StockGenMark Diagnostics, Inc. (GNMK) SVP Sells $12,888.06 in Stock
www.americanbankingnews.com - November 21 at 9:56 PM
Hany Massarany Sells 8,252 Shares of GenMark Diagnostics, Inc. (GNMK) StockHany Massarany Sells 8,252 Shares of GenMark Diagnostics, Inc. (GNMK) Stock
www.americanbankingnews.com - November 21 at 9:34 PM
Scott Mendel Sells 2,879 Shares of GenMark Diagnostics, Inc. (GNMK) StockScott Mendel Sells 2,879 Shares of GenMark Diagnostics, Inc. (GNMK) Stock
www.americanbankingnews.com - November 21 at 9:32 PM
GenMark Diagnostics, Inc. (GNMK) Given a $11.00 Price Target by BTIG Research AnalystsGenMark Diagnostics, Inc. (GNMK) Given a $11.00 Price Target by BTIG Research Analysts
www.americanbankingnews.com - November 21 at 8:14 PM
ETFs with exposure to GenMark Diagnostics, Inc. : November 21, 2017ETFs with exposure to GenMark Diagnostics, Inc. : November 21, 2017
finance.yahoo.com - November 21 at 7:08 PM
GNMK INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of GenMark Diagnostics, Inc. InvestorsGNMK INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of GenMark Diagnostics, Inc. Investors
finance.yahoo.com - November 14 at 7:41 PM
Head-To-Head Contrast: GenMark Diagnostics (GNMK) versus Cerner Corporation (CERN)Head-To-Head Contrast: GenMark Diagnostics (GNMK) versus Cerner Corporation (CERN)
www.americanbankingnews.com - November 14 at 7:18 PM
ACT NOW: Monteverde & Associates PC Announces an Investigation of GenMark Diagnostics, Inc. - GNMKACT NOW: Monteverde & Associates PC Announces an Investigation of GenMark Diagnostics, Inc. - GNMK
finance.yahoo.com - November 12 at 9:57 AM
ETFs with exposure to GenMark Diagnostics, Inc. : November 9, 2017ETFs with exposure to GenMark Diagnostics, Inc. : November 9, 2017
finance.yahoo.com - November 11 at 7:23 AM
Glancy Prongay & Murray LLP Continues Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)Glancy Prongay & Murray LLP Continues Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)
finance.yahoo.com - November 11 at 7:23 AM
GenMark Diagnostics, Inc. (GNMK) Given Average Recommendation of "Hold" by AnalystsGenMark Diagnostics, Inc. (GNMK) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 9 at 7:44 AM
GenMark Diagnostics, Inc. (GNMK) Expected to Post Quarterly Sales of $19.99 MillionGenMark Diagnostics, Inc. (GNMK) Expected to Post Quarterly Sales of $19.99 Million
www.americanbankingnews.com - November 9 at 2:48 AM
GenMark Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics ForumGenMark Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
finance.yahoo.com - November 8 at 8:07 AM
GNMK INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of GenMark Diagnostics, Inc. InvestorsGNMK INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of GenMark Diagnostics, Inc. Investors
finance.yahoo.com - November 8 at 8:07 AM
 Analysts Anticipate GenMark Diagnostics, Inc. (GNMK) to Announce -$0.19 EPS Analysts Anticipate GenMark Diagnostics, Inc. (GNMK) to Announce -$0.19 EPS
www.americanbankingnews.com - November 7 at 9:34 PM
GenMark Diagnostics, Inc. (GNMK) Director Acquires $82,600.00 in StockGenMark Diagnostics, Inc. (GNMK) Director Acquires $82,600.00 in Stock
www.americanbankingnews.com - November 6 at 3:36 PM
GenMark Diagnostics, Inc. (GNMK) Issues  Earnings Results, Misses Estimates By $0.02 EPSGenMark Diagnostics, Inc. (GNMK) Issues Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - November 4 at 2:36 PM
Edited Transcript of GNMK earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of GNMK earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 1:56 AM
GenMark Diagnostics, Inc. (GNMK) Insider Sells $11,497.12 in StockGenMark Diagnostics, Inc. (GNMK) Insider Sells $11,497.12 in Stock
www.americanbankingnews.com - November 3 at 9:44 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenMark Diagnostics, Inc. (GNMK)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenMark Diagnostics, Inc. (GNMK)
finance.yahoo.com - November 3 at 8:55 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GenMark Diagnostic, Inc. - GNMKSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GenMark Diagnostic, Inc. - GNMK
finance.yahoo.com - November 3 at 8:55 PM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)Glancy Prongay & Murray LLP Commences Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)
finance.yahoo.com - November 3 at 8:55 PM
GenMark Diagnostics, Inc. (GNMK) Stock Rating Reaffirmed by Cowen and CompanyGenMark Diagnostics, Inc. (GNMK) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - November 3 at 7:50 PM
GenMark Diagnostics, Inc. (GNMK) Rating Reiterated by Raymond James Financial, Inc.GenMark Diagnostics, Inc. (GNMK) Rating Reiterated by Raymond James Financial, Inc.
www.americanbankingnews.com - November 3 at 8:52 AM
GenMark Diagnostics, Inc. (GNMK) PT Lowered to $11.00 at Needham & Company LLCGenMark Diagnostics, Inc. (GNMK) PT Lowered to $11.00 at Needham & Company LLC
www.americanbankingnews.com - November 3 at 8:52 AM
GenMark Diagnostics, Inc. to Host Earnings CallGenMark Diagnostics, Inc. to Host Earnings Call
finance.yahoo.com - November 2 at 9:46 PM
GenMark Diagnostics Reports Third Quarter 2017 ResultsGenMark Diagnostics Reports Third Quarter 2017 Results
finance.yahoo.com - November 2 at 9:46 PM
GenMark Diagnostics reports 3Q lossGenMark Diagnostics reports 3Q loss
finance.yahoo.com - November 2 at 9:46 PM
ETFs with exposure to GenMark Diagnostics, Inc. : October 30, 2017ETFs with exposure to GenMark Diagnostics, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 8:01 PM
Head to Head Analysis: Fulgent Genetic (FLGT) vs. GenMark Diagnostics (GNMK)Head to Head Analysis: Fulgent Genetic (FLGT) vs. GenMark Diagnostics (GNMK)
www.americanbankingnews.com - October 28 at 3:04 AM
GenMark Diagnostics, Inc. (GNMK) to Release Earnings on WednesdayGenMark Diagnostics, Inc. (GNMK) to Release Earnings on Wednesday
www.americanbankingnews.com - October 25 at 4:58 AM
GenMark Diagnostics Schedules Third Quarter 2017 Financial Results Conference Call for November 2, 2017GenMark Diagnostics Schedules Third Quarter 2017 Financial Results Conference Call for November 2, 2017
www.businesswire.com - October 21 at 1:13 AM
Head to Head Comparison: GenMark Diagnostics (GNMK) & Danaher Corporation (DHR)Head to Head Comparison: GenMark Diagnostics (GNMK) & Danaher Corporation (DHR)
www.americanbankingnews.com - October 20 at 6:28 AM
 Analysts Expect GenMark Diagnostics, Inc. (GNMK) Will Post Quarterly Sales of $14.21 Million Analysts Expect GenMark Diagnostics, Inc. (GNMK) Will Post Quarterly Sales of $14.21 Million
www.americanbankingnews.com - October 20 at 1:58 AM
GenMark Diagnostics, Inc. (GNMK) Given Buy Rating at Needham & Company LLCGenMark Diagnostics, Inc. (GNMK) Given Buy Rating at Needham & Company LLC
www.americanbankingnews.com - October 19 at 6:58 PM
GenMark Diagnostics, Inc. (GNMK) Expected to Post Earnings of -$0.29 Per ShareGenMark Diagnostics, Inc. (GNMK) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - October 19 at 12:14 AM
RSI Alert: GenMark Diagnostics (GNMK) Now OversoldRSI Alert: GenMark Diagnostics (GNMK) Now Oversold
www.thestreet.com - October 18 at 12:53 AM
ETFs with exposure to GenMark Diagnostics, Inc. : October 16, 2017ETFs with exposure to GenMark Diagnostics, Inc. : October 16, 2017
finance.yahoo.com - October 16 at 3:50 PM
GenMark Diagnostics, Inc. (GNMK) Given Consensus Rating of "Buy" by BrokeragesGenMark Diagnostics, Inc. (GNMK) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 15 at 9:28 AM
Is GenMark Diagnostics Inc (GNMK) Undervalued?Is GenMark Diagnostics Inc (GNMK) Undervalued?
finance.yahoo.com - October 12 at 8:03 PM
Critical Comparison: GenMark Diagnostics (GNMK) versus Its PeersCritical Comparison: GenMark Diagnostics (GNMK) versus Its Peers
www.americanbankingnews.com - October 12 at 12:28 AM

SEC Filings

GenMark Diagnostics (NASDAQ:GNMK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GenMark Diagnostics (NASDAQ:GNMK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GenMark Diagnostics (NASDAQ GNMK) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.